Genetically engineered distal airway stem cell transplantation protects mice from pulmonary infection

Yue-qing Zhou1,†, Yun Shi2,3,†, Ling Yang1,†, Yu-fen Sun1, Yu-fei Han1, Zi-xian Zhao1, Yu-jia Wang1, Ying Liu2, Yu Ma2,4, Ting Zhang4, Tao Ren2, Tina P Dale5, Nicholas R Forsyth5,†, Fa-guang Jin6, Jie-ming Qu6,7,*†, Wei Zuo1,2,4,8,9,**† & Jin-fu Xu1,***†

Abstract

Severe pulmonary infection is a major threat to human health accompanied by substantial medical costs, prolonged inpatient requirements, and high mortality rates. New antimicrobial therapeutic strategies are urgently required to address the emergence of antibiotic resistance and persistent bacterial infections. In this study, we show that the constitutive expression of a native antimicrobial peptide LL-37 in transgenic mice aids in clearing Pseudomonas aeruginosa (PA01), a major pathogen of clinical pulmonary infection. Orthotopic transplantation of adult mouse distal airway stem cells (DASCs), genetically engineered to express LL-37, into injured mouse lung foci enabled large-scale incorporation of cells and long-term release of the host defense peptide, protecting the mice from bacterial pneumonia and hypoxemia. Further, correlates of DASCs in adult humans were isolated, expanded, and genetically engineered to demonstrate successful construction of an anti-infective artificial lung. Together, our stem cell-based gene delivery therapeutic platform proposes a new strategy for addressing recurrent pulmonary infections with future translational opportunities.

Keywords antimicrobial peptide; distal airway stem cells; pulmonary infection; transplantation

Subject Categories Immunology; Respiratory System

Introduction

Respiratory infection is amongst the leading causes of human death. These include lower respiratory tract infections by Gram-negative pathogens such as Pseudomonas aeruginosa which constitute the main reason for hospital-associated infections and are associated with high morbidity and mortality rates in hospitals. These continue to pose a therapeutic challenge due to the rapid development of resistance to standard antibiotic regimes during treatments. In the case of the opportunistic pathogen P. aeruginosa, broad antibiotic resistance has been observed, and 18–25% of clinical isolates demonstrated multidrug resistance (Souli et al., 2008). Unfortunately, relapse or re-infection is a frequent occurrence in patients with pulmonary infections. To this end, the development of new therapeutic strategies is needed to combat pulmonary bacterial infections.

Antimicrobial peptides (AMPs) are substances produced by animals, bacteria, and plants that are regarded as naturally occurring broad-spectrum antibiotics. As an essential part of innate immunity, AMPs possess the ability to kill invading pathogens including bacteria, fungi, virus, and parasites (Zasloff, 2002; Fjell et al, 2011; Kovach et al, 2012). The peptide hCAP-18/LL-37 (LL-37) is the only human cathelicidin (CAMP) identified so far. The LL-37 peptide is cleaved from hCAP-18 by proteinase, which enables it to have a broad range of bactericidal activity against both Gram-negative and Gram-positive organisms, including P. aeruginosa. LL-37 has roles in multiple host defense processes by directly targeting microbial biofilm and activating innate immune cell function (Scott...
et al, 2002; Overhage et al, 2008; Yu et al, 2010; Bandurska et al, 2015). In the inflamed human lung, LL-37 was highly expressed and had potent anti-infective and anti-inflammatory potential (Nijnik & Hancock, 2009; Currie et al, 2016), suggesting that the LL-37 peptide may be used as an alternative medicine to conventional antibiotics for treating pulmonary infection. However, the degradation of the LL-37 peptide in vivo due to bacterial proteases may limit its clinical application (Vandamme et al, 2012). Furthermore, as a peptide with potential off-target toxicity, LL-37 requires topical delivery to infected foci, rather than systemically, with local concentration control (Johansson et al, 1998; Heilborn et al, 2005). Therefore, the development of a system to achieve local, long-term LL-37 release may help combat pulmonary infection.

Viral systems have been utilized for exogenous gene expression; however, clinical applicability for this approach has multiple drawbacks including virus-induced tissue toxicity and inflammation post-virus infection, oncogenic risks and genotoxicity, and the off-target effects of the viral vector (i.e., liver). Here, we introduce a novel platform combining conventional viral-based gene engineering with intrapulmonary stem cell transplantation. We and others previously demonstrated that distal airway stem cells (DASCs) derived from p63+ lineage negative progenitors are the major regenerative cells following large-scale lung damage (Kumar et al, 2011; Vaughan et al, 2015; Zuo et al, 2015; Yang et al, 2018). DASCs have the capacity to rapidly restore epithelial barriers in vivo and differentiate into functional alveolar cells with accompanied Notch signaling (Vaughan et al, 2015; Xi et al, 2017). The feasibility for large-scale in vitro expansion and remarkable lung engraftment after transplantation (Zuo et al, 2015; Imai-Matsushima et al, 2018) make DASCs ideal candidates for cell therapy and gene engineering.

In the current study, via a novel transgenic rodent model, we show that constitutive expression of human LL-37 peptide, in the lung, enhances the pulmonary host defense system. Introduction of LL-37 into mouse DASCs enable delivery of the antimicrobial peptide specifically into injured foci without distribution to other healthy lung regions, and endow the lung with enhanced bacterial clearance ability. An anti-infective human bioengineered lung is also constructed by engrafting LL-37-overexpressing human DASCs into decellularized lung scaffolds. Taken together, we demonstrate that genetically engineered DASCs can efficiently and specifically deliver the antimicrobial peptide LL-37 in vivo and protect the lung against pathogen infection.

Results

Constitutive LL-37 expression clears pulmonary infection in vivo

Clinical observations have indicated that overexpression of LL-37 expression in lung disease exacerbation (Schaller-Bals et al, 2002; Pouwels et al, 2015), suggesting that pulmonary infection and inflammation could activate the LL-37-based protective mechanism. Here, to understand whether the elevated expression of LL-37 in vivo is beneficial, we constructed a novel transgenic mouse strain that constitutively expressed the human hCAP-18 gene driven by the EF1a promoter (Fig 1A). The expressed 18-kD hCAP-18 precursor required additional processing to produce 4-kD LL-37 and acquired biological functionality. To detect LL-37 expression, we collected the lysate from wild-type FVB and LL-37 transgenic mice and concentrated low-molecular-weight proteins by passing through a 10-kD centrifugal filter device. The expression of 4-kD LL-37, but not larger proteins (i.e., GAPDH), was detected in the low-molecular-weight ultrafiltrate in the transgenic mice (Fig 1B).

Bronchoalveolar lavage fluid (BALF) ultrafiltrate from LL-37 transgenic mice demonstrated a moderately enhanced bacterial inhibitory function than wild-type FVB BALF when used to culture PAO1 in vitro. In contrast, high-molecular-weight retentates displayed little difference in their bacterial inhibitory effect (Fig 1C). We also challenged mouse lung with equal amounts of PAO1 (5 x 10^6 CFU of PAO1) and analyzed the lung homogenate at different time points after infection. The results showed that the LL-37 transgenic mice had significantly enhanced bacterial clearance compared to wild-type FVB mice, leaving residual infection (Fig 1D). Histological analysis indicated that LL-37 transgenic mice lung tissue displayed alleviated alveolar tissue damage at 6 h after PAO1 infection, potentially due to reduced bacterial burden (Fig 1D–F). Furthermore, the mRNA levels of major pro-inflammatory cytokines including IL-6 and IL-1β decreased in the lungs of LL-37 transgenic mice (Fig 1G).

To further characterize the LL-37 transgenic mouse lung before and after bacterial infection, we performed RNA-Seq on lung tissues to analyze their whole transcriptomic profiles. As expected, FVB lungs had distinct transcriptomic profiles before and after PAO1 infection (PCC = 0.672). In contrast, LL-37+/+ lungs shared highly similar whole transcriptomic profiles before and after PAO1 infection (PCC = 0.977), suggesting that the LL-37+/+ lungs were protected from PAO1 challenge-induced alterations (Fig 2A). Interestingly, we found that overexpression of LL-37 gave rise to upregulation of multiple immune response-related genes even prior to infection (Fig 2B). Further analysis on gene ontology revealed that LL-37 expression enhanced normal mouse development, including muscle, and blood circulation, and augmented mucosal immune response and organ-specific immune responses (Fig 2C). This finding indicated that LL-37 could stimulate lung immunity to protect infection, which was consistent with previous reports on other cathelicidin or cathelicidin-related peptides (Kovach et al, 2012; Beaumont et al, 2014).

Next, we analyzed the lung transcriptomic profiles after PAO1 infection. The infected FVB mouse lungs were characterized by elevated infection and immune-related processes, such as “defense response” and “leukocyte activation”; in contrast, the infected LL-37+/+ lungs were characterized by lung tissue homeostasis/development-related processes, such as “lung epithelium development,” “respiratory system development,” and “cilium” (Fig 2D and Table EV1). Protein–protein interaction network analysis of overexpressed genes identified an inflammation-related molecular network in infected WT lungs, and in contrast, a lung development-related molecular network in infected LL-37+/+ lungs (Fig 2E). These data indicate that constitutive LL-37 expression in mouse lung can protect the lung from bacterial infection and inflammation.

Genetically engineered mDASCs express functional LL-37 peptide

LL-37 aids bacterial clearance in the mouse lung. We next determined if this peptide could be used in combination with DASCs to protect damaged lung from infection. P63+/Krt5+ DASCs (mDASCs) were isolated from normal adult mouse lung and expanded on 3T3
feeder cells as stem cell clones. The LL-37 gene was introduced into mDASCs by lentiviral transduction. Constitutive LL-37 expression was detected at both RNA and protein levels in LL-37-mDASCs but not in their wild-type counterpart (Fig 3A–C). WT-mDASCs and LL-37-mDASCs expressed similar levels of stem cell markers P63 and Krt5 (Fig 3D). mDASCs, irrespective of types, were able to be passaged indefinitely in our system. Elevated LL-37 expression was previously reported to affect cell viability and proliferation (Heilborn et al, 2005), while in this study we did not detect significant differences in either proliferation rate (Fig EV1A) or clonogenic ability (Fig 3E). In a three-dimensional organoid culture system, both mDASC cell lines formed alveolar-like sphere structures consisting of differentiated cells expressing AQP5 and PDPN, type I alveolar cell markers (Fig 3F). To confirm that genetically modified mDASCs were not tumorigenic, we assessed the anchorage-independent growth potential of these cells. mDASCs after LL-37 lentiviral transduction were unable to grow in soft agar medium, while mouse melanoma cells (B16) exhibited robust colony-forming efficiency.

© 2019 The Authors

EMBO Molecular Medicine e10233 | 2019 3 of 16
under identical conditions (Fig EV1B). This indicated the successful generation of a LL-37-expressing mDASC cell line with unaltered self-renewal and differentiation properties.

To test whether functional LL-37 peptide could be produced and secreted by LL-37-mDASCs, we assessed the bacterial clearance ability of their culture-conditioned medium (CM). PAO1 growth was significantly inhibited by the CM from LL-37-mDASCs but not from WT-mDASCs (Fig EV1C). In a series of cell/bacteria co-culture assays, LL-37-mDASCs, when compared to WT-mDASCs, showed impaired bacterial growth of PAO1 at different infection doses and time points, although substantial bacterial proliferation was observed under both conditions (Fig 3G–I). A similar bacterial growth inhibitory effect of LL-37-mDASCs was also detected with Gram-negative pathogen, *Escherichia coli*.
Figure 3. Engineered mDASCs possessed normal stem cell properties and enhanced antimicrobial potency.

A–C Detection of LL-37 expression in the engineered mDASCs by immunofluorescence (A), real-time quantitative PCR (B), and Western blot (C). Scale bar, 50 μm. BF, bright field. n = 10. Error bars, SEM.

D Anti-Krt5 (red) and anti-P63 (green) immunostaining of WT- and LL-37-mDASC colonies. Scale bar, 70 μm.

E Stem cell colony-forming efficiency of WT- and LL-37-mDASCs during five serial passages. n = 6. Error bars, SD.

F Representative 3D organoid culture of mDASCs with expression of type I alveolar cell markers (Aqp5 and Pdpn). Left panels, bright-field imaging of 3D organoids. Right panels, immunofluorescence of organoid sections. Scale bar, 20 μm.

G Co-culture of bacteria with DASCs shows antimicrobial effects in dose-dependent manner. Initial additions of PAO1 were 0.1 × , 0.5 × and 1 × 10^4 CFU, respectively. Co-culture duration, 6 h. n = 4. Error bars, SEM. MOI, multiplicity of infection.

H Co-culture of bacteria with DASCs shows antimicrobial effects in time-dependent manner. Initial concentration of PAO1 was 1 × 10^4 CFU. MOI = 1. n = 3. Error bars, SEM.

I, J Preincubation of cells with anti-LL-37 antibody, but not IgG control, significantly reduced anti-PAO1 (I) and anti-Escherichia coli (J) effects of LL-37-mDASCs. Initial dose of bacteria was 10^7 CFU. Co-culture duration, 18 h. n = 4 in (I) and n = 3 in (J). Error bars, SEM.

Data information: Statistics for graphs: unpaired two-tailed t-test (B), two-way ANOVA followed by Sidak’s test (G, H) and one-way ANOVA followed by Tukey’s test (I, J). *P < 0.05; **P < 0.01; ****P < 0.0001.

Source data are available online for this figure.
(Figs 3J and EV1D and E). To confirm that the inhibitory effect of engineered cells was attributed to LL-37 peptide production, we used anti-LL-37 antibody to neutralize the secreted peptide. Compared with IgG control, anti-LL-37 antibody compromised the inhibitory effect of LL-37-mDASCs (Fig 3I and J) and their cellular CM (Fig EV1F). Collectively, the above data demonstrate successful engineering of LL-37-mDASCs with normal stem cell properties and antimicrobial functions.

Regeneration of LL-37-Lung by transplantation of genetically engineered mDASCs

To investigate the potential therapeutic effect of engineered DASCs in vivo, we transplanted the LL-37-mDASCs into the damaged lung of syngeneic animals. The chemotherapeutic drug bleomycin was intratracheally instilled into the mouse lung to induce acute pulmonary inflammation and alveolar tissue damage. Seven days after bleomycin administration, 10⁶ GFP-labeled WT-mDASCs or LL-37-mDASCs were intratracheally delivered into injured mouse lungs. We named the lungs with WT-mDASCs or LL-37-mDASCs engraftment as WT-Lung or LL-37-Lung, respectively. The lung tissues were harvested for analysis on different days after transplantation. Substantial incorporation of mDASCs into mouse lung was detected without observing significant rejection of cells (Fig 4A). An equal engraft ratio was observed for the two cell types, which both peaked around 21 days after transplantation and remained stable thereafter (Fig 4B). Tissue sectioning and analysis showed a broad distribution of stem cells and their progeny in mouse lung parenchyma with a substantial proportion differentiated into air sac-like structures with type I alveolar cell marker AQPS co-staining (Figs 4C and EV2A). A population of transplanted engineered cells continued to express the proliferation marker Ki67 up to 28 days after transplantation (Fig 4D), suggesting their high viability and extended contribution to the tissue regeneration process.

For the LL-37-mDASC group, constitutive LL-37 expression was specifically detected in the lung area with GFP⁺ stem cell incorporation (Figs 5A and EV2B). Importantly, there was no incorporation of GFP⁺ stem cells in the uninjured lung (Fig EV2C), indicating specific targeting of LL-37 toward injured but not healthy lung tissue.

Regenerated LL-37-Lung has enhanced bacterial clearance ability

Previously, the capacity of LL-37 to enhance pulmonary bacterial clearance 6 and 24 h post-PAO1 infection has been demonstrated (Beaumont et al., 2014). To assess whether the LL-37-Lung had enhanced host defense post-bacterial infection, WT-Lung and LL-37-Lung were challenged with intratracheal delivery of PAO1 (Fig EV2D). The PAO1 load levels in mouse lung were quantified by bacterial culture 6, 24, and 48 h after infection. LL-37-Lung had significantly less PAO1 load in the whole lung homogenate (Fig 5B) as well as in BALF (Fig 5C). A similar effect was observed when the lungs were challenged with E. coli (Fig EV2E) 48 h after infection. Correspondingly, differentially expressed genes measured by RNA-Seq between infected WT-Lungs and LL-37-Lungs indicated that LL-37 expression alleviated the inflammation reaction and downregulated the related pro-inflammatory pathways (Fig 5D and E). Consequently, 2 days after infection, the mice with LL-37-Lung demonstrated healthier pulmonary function, as shown by the higher O₂ partial pressure and O₂ saturation, yet lower CO₂ partial pressure in arterial blood (Figs 5F and EV2F). Altogether, the data above showed that the LL-37-expressing mDASC engraftment could protect mouse lung from bacterial infection and improve the pulmonary function of infected recipients.

Two days after infection, we investigated the effects of LL-37-mDASCs on histopathological changes in lung injury (Fig 6A and B for PAO1 infection and Fig EV2G for E. coli infection). Intratracheal bleomycin administration caused acute alveolar damage and inflammation aggravated by bacterial infection. However, the destructive changes to the lung were significantly attenuated by LL-37-mDASCs and lung injury scores were significantly decreased, compared to the WT-mDASC treated mice. Levels of CD68 protein, a marker for macrophages, were also examined by immunohistochemistry (Fig 6C and D). The data showed an increase of CD68 expression in lung tissues following bleomycin + PAO1 treatment, which was significantly alleviated by treatment with LL-37-mDASCs. Real time qPCR analysis of major pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 showed a less severe inflammatory response in the LL-37-Lung after infection (Fig 6E).

LL-37-expressing human DASC engraftment protects bioengineered artificial lung from bacterial infection

Following on from our demonstration that DASCs can be successfully engrafted into native lung, we next assessed engraftment into a bioengineered artificial lung. Bioengineered artificial lungs are a highly promising alternative organ source for clinical lung transplant surgery, given that suitable, autologous source seed cells are used to reconstruct functional epithelium and avoid immune rejection (Petersen et al., 2010). Furthermore, infection before and after organ transplant surgery is a major hindrance to successful organ transplants, and development of an anti-infective bioengineered organ may provide a functional alternative.

To test the feasibility of artificial lung construction with human DASCs (hDASCs), we isolated adult hDASCs from the sixth-order airway of bronchiectasis patients by bronchoscopic brushing followed by large-scale cell expansion on irradiated 3T3-J2 feeder cells (Hackett et al., 2011; Ma et al., 2018; Fig 7A). The LL-37 expression level in wild-type hDASCs was barely detectable. A lentiviral system was used to stably overexpress LL-37 up to a thousand-fold (Figs 7B, and EV3A and B). We expanded the engineered hDASCs as homogeneous, immature clones to indefinite culture and achieved approximately 100 million cells in < 3 weeks.

To construct bioengineered artificial lungs, we harvested rat lungs and decellularized them by airway perfusion, as previously reported (Gilpin et al., 2016). Complete removal of cellular components and proper preservation of extracellular matrix were demonstrated by morphologic and cell nucleus analyses (Figs 7C and EV3C). GFP-labeled WT- and LL-37-hDASCs were then delivered into the lung through the trachea by gravity to repopulate the scaffold and maintained the decellularized lung in ex vivo biomimetic culture for 7 days (Fig 7D). Large-scale cellular engraftment was detected by direct GFP fluorescence observation (Fig 7E). Immunofluorescence staining showed that most cells preserved the KRT5⁺ hDASC phenotype (Fig EV3D). However, we found that a
Few grafted cells acquired an elongated shape with AQP5 marker expression, suggesting the gradual maturation of these stem cells into type I alveolar cells (Fig EV3E).

Substantial LL-37 expression was detectable in LL-37-hDASC recellularized lungs (Fig 7F). Successfully recellularized lungs were co-cultured with PAO1 or E. coli to examine their inhibiting growth ability. The results showed, compared to wild-type ones, that the LL-37-hDASC recellularized lungs had improved bacterial clearance ability (Fig 7G). Collectively, the above work proposes a novel genetic and stem cell-based therapeutic strategy for the treatment of recurrent, antibiotic-resistant pulmonary infections.

**Discussion**

Here, we have demonstrated that constitutive expression of LL-37 peptide can protect the lung from bacterial infection, and transplantation of LL-37-expressing DASCs can be used to regenerate lung...
with enhanced host defense capability. Considering that respiratory infection has become the leading reason for human death and the number of antibiotic-resistant cases is constantly increasing (Theuretzbacher & Toney, 2006), the concept of host defense augmentation is an attractive approach with great clinical potential (Finlay & Hancock, 2004; Spellberg et al, 2004; Easton et al, 2009).

LL-37 plays a key role in inhibiting the formation of *P. aeruginosa* biofilm at lower concentrations and directly degrades biofilms at higher concentrations (Dean et al, 2011). Moreover, the anti-infection mechanism of LL-37 in vivo is likely to be more complex than simple direct microbicidal effects. Systematic administration of LL-37 protects mice from pulmonary bacterial infection (Beaumont et al, 2014), and transfer of LL-37 restored bacterial killing in a cystic fibrosis xenograft model (Bals et al, 1999a). Systemic expression of
LL-37/hCAP-18 after intravenous injection also resulted in improved survival rates following intravenous injection of lipopolysaccharide with galactosamine or *E. coli* (Bals et al., 1999b).

Wild-type mice challenged with *P. aeruginosa*, pro-inflammatory cytokines, and chemokines, including Il-6, Il-1, and Cxcl1, were significantly recruited. Yet, infection and inflammation of LL-37+/+ mice were reduced, as confirmed by transcriptomic analysis. Both Wnt and FGF signals, recognized as key factors in pulmonary development and regeneration (Shu et al., 2005; Zacharias et al., 2018), were also activated in infected LL-37+/+ mice. We used DASCs as a vehicle for LL-37 antimicrobial peptide to achieve improved delivery. The incorporated DASCs itself could rapidly establish the epithelium barrier, which seems to have protective effects on pulmonary infection, while LL-37-DASCs have even stronger protective effects than WT-DASC. As DASCs will not incorporate into healthy pulmonary tissue or other tissues or organs, our current strategy ensured the localized distribution of LL-37-DASCs to injured lung foci, where they can concentrate to combat local pulmonary infection with little or no side-effects on other healthy tissue or organs. Meanwhile, LL-37-DASCs avoid limitations such as fast degradation following direct application of synthetic LL-37. At the same time, we have shown that overexpression of LL-37 impacts neither the viability of host cells nor the general health of LL-37 transgenic mice. All the above data show the evidence that LL-37-DASCs provide a promising therapeutic exploration for lung infection. However, the potential risk associated with longer-term release of LL-37 in vivo needs to be fully investigated as well.

We also used LL-37-hDASCs to recellularize lung scaffolds and successfully established an anti-infective bioengineered lung. It should be noted that the bioengineered lung built in the current work is only conceptual and could not contribute to recipient pulmonary function, even if transplanted, due to lack of proper vasculature. However, it demonstrated an important proof of concept, namely, that patient-specific DASCs could be isolated and genetically engineered to build artificial organs with demanding biological functions.
Figure 7. Lung scaffold recellularized by LL-37 engineered human DASCs has enhanced anti-bacterial ability.

A. Anti-Krt5 (red) and anti-P63 (green) immunofluorescence of isolated hDASCs. Scale bar, 90 μm.
B. The mRNA expression levels of LL-37 were measured by real-time qPCR for WT- and LL-37-hDASCs. n = 5. Error bars, SEM.
C. H&E staining of native rat lung tissue and decellularized scaffold showed the absence of nuclei following decellularization. Scale bar, 40 μm.
D. Ex vivo biomimetic culture of LL-37-hDASCs recellularized lungs with constant media perfusion.
E. Direct fluorescence image showing GFP-labeled LL-37-hDASCs before (left) and 7 days after (right) being engrafted onto the decellularized scaffold. Scale bar, 50 μm (right panel) and 2,000 μm (right panel).
F. Immunofluorescence of recellularized lung with indicated antibodies. Blue color indicates nuclear DAPI staining. Scale bar, 50 μm.
G. The recellularized lung by LL-37-hDASCs displayed growth inhibitory effect on PAO1 and Escherichia coli. Initial dose of bacteria was $2 \times 10^4$ CFU. Culture duration, 24 h. n = 6. Error bars, SEM.

Data information: Statistics for graphs: unpaired two-tailed t-test (B) and one-way ANOVA followed by Tukey’s test (C). *P < 0.05, **P < 0.001, ***P < 0.0001.

Source data are available online for this figure.
In addition to DASCs, many other distinct populations of adult lung stem/progenitor cells have been reported to exert regenerative functions under different circumstances (Barkauskas et al., 2013; Leeman et al., 2014; Nabhan et al., 2018). Among them, only DASCs were tested in the current study, as such cells were easily expanded, genetically manipulated, and transplanted into the damaged lung. We did observe a fraction of transplanted LL-37-DASCs differentiating into mature alveolar cells \textit{in vivo}. However, even undifferentiated, the engrafted LL-37-DASCs could rapidly establish an epithelial barrier to prevent the spread of bacteria and inflammation while maintaining the local antimicrobial peptide concentration. Once the bacteria were gradually cleared by LL-37 and other immune factors, the improved microenvironment could further accelerate LL-37-DASC maturation process. We anticipate that similar genetic engineering strategies can also be applied to other lung stem/progenitor cell types—including but not limited to type II alveolar cells—that might exert synergistic effects on lung repair following transplantation.

In clinical practice, genetically engineered cells are being recognized as powerful “living drugs” for treating many previously uncured diseases. For example, substantial advances have been made in the field of T-cell-mediated cancer therapy. Based on this technique, T cells are genetically modified by viral vector transduction that either alter T-cell receptor (TCR) specificity or introduce antibody-like recognition into chimeric antigen receptors (CARs) (Sadelain et al., 2017). The successful application of genetically engineered T cells is encouraging the field to develop more gene- and cell-based therapies. As LL-37 peptide has already demonstrated safety and efficacy in human infectious disease treatment (Gronberg et al., 2014) and human DASC transplantation was also previously tested in a pilot clinical trial (Ma et al., 2018), we think their combination could lead to a promising practical therapy with great clinical potential for those life-threatening lung infections.

### Materials and Methods

#### Animals and bacteria

Female C57/B6 mice and wild-type FVB mice (6–8 weeks) weighing 16–18 g were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (China). LL-37+/+ mice (Fvb background) were produced by Cyagen Biosciences Inc. (China). Male Sprague-Dawley rats, weighing 180–220 g each were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (China). All mice were housed in specific pathogen-free conditions within an animal care facility (Center of Laboratory Animal, Tongji University, Shanghai, China) until euthanasia. All animals were cared for in accordance with NIH guidelines, and all animal experiments were performed under the guidance of, and with approval from, the Institutional Animal Care and Use Committee of Tongji University. *Pseudomonas aeruginosa* (ATCC-BAA-47; strain HER-1018/PAO1) and *E. coli* strain DH5-α (ATCC-98489) were used in these experiments.

#### Generation of LL-37+/+ transgenic mice

All animal experiments were performed according to guidelines approved by the Tongji University Association for Laboratory Animal Science. To understand whether the expression of LL-37 is beneficial \textit{in vivo}, we constructed a transgenic mouse that expressed the human CAMP gene. To begin with, we constructed the LL-37-expressing plasmid. Full-length human CAMP cDNA (NCBI: NM_004345.4) was inserted into an IRES vector with a GFP expression sequence under a constitutively active EF-1α promoter. Next, fertilized eggs obtained from FVB background mice were injected with the pRES human LL-37 expression plasmid described above and then implanted into FVB females to generate LL-37 founders. Then LL-37+/+ mice were identified using genotyping PCR for LL-37 gene expression, which was performed on tails that were obtained from mice aged 3–4 weeks old. PCR was performed using the following primers: LL-37 F: 5’-AGCAGTCACAGAGATTGT-3’ and LL-37 R: 5’-GGCACACACTGAGACTCAGT-3’. The PCR product produced by LL-37+/+ mice was 135 bp long. LL-37 protein expression was analyzed using Western blotting analysis. PCR-negative littersmates and wild-type (FVB) mice were used as controls.

#### Tissue histology and immunohistochemistry

For mouse lung histology analysis, mice were euthanized and the diaphragm was carefully cut to open without touching the lung. Lung was inflated with 3.7% formaldehyde (Sigma, USA) using a 30G needle through trachea. Then the lung was dissected and fixed in 3.7% formaldehyde at 4°C overnight before paraffin section or cryosection.

For cryosection, the fixed lung was settled by 30% sucrose before embedding into the Tissue-Tek O.C.T compound (Sakura, Japan), solidified on dry ice, and cut using cryotome (Leica Microsystems, Germany) into 5- to 10-μm thickness. For paraffin section, the lung was dehydrated by gradient ethanol in an automatic tissue processor and then embedded into paraffin blocks. The blocks were cut into 5- to 7-μm thickness by using microtome (Leica Microsystems, Germany) at distinct planes. The sections were placed on polylysine coated glass slides and stored at room temperature until further use. Hematoxylin and eosin (H&E) staining was performed following standard protocol. The lung injury score was calculated as previously described (Matute-Bello et al., 2011). For immunostainings, sections were deparaffinized, rehydrated, and blocked by 0.3% H2O2 for 30 min. Antigen retrieval was performed by treating the slides in citrate buffer in a microwave oven for 10 min. The slides were incubated for 1 h with normal goat serum, and then incubated in a moist chamber with anti-CD68 (ab125212, Abcam) antibody at 4°C overnight. After a complete wash in phosphate-buffered saline (PBS), the tissues were incubated in biotin-labeled goat anti-mouse antibody for 30 min and rinsed with PBS, and incubated with avidin–biotin–peroxidase complex for 30 min at 37°C. The signal was detected using diaminobenzidine (DAB). Brown-stained area (CD68+ cells in the monocyte lineage) was separately quantified by Image J version 1.52a.

#### Immunofluorescence

For immunofluorescence staining, cells or tissues were fixed with 3.7% formaldehyde, and then incubated with 0.2% Triton X-100 to improving the cell permeability for 10 min. Paraffin- or cryo-embedded tissues were sectioned and subjected to antigen retrieval in citrate buffer (pH 6.0, Sigma, USA) in microwave oven for 20 min before staining. Normal donkey serum at 10% concentration was used as controls.
RNA sequencing analysis and bioinformatics

For RNA sequencing, lungs were dissected in ice-cold phosphate-buffered saline and lungs from FVB/LL-37+/+ or GFP+ lobe from WT-Lung/LL-37-Lung were dedicated for RNA isolation. Total RNA was extracted using TRIzol Reagent (Invitrogen, LifeTechnologies, USA) following the manufacturer’s instructions, and then treated with DNase I (Invitrogen, Life Technologies, USA). The RNA integrity was verified using an Agilent 2100 BioAnalyzer (Agilent, USA). The CDNA library construction and sequencing were performed using BGISEQ-500 platform. High-quality reads were aligned to the mouse reference genome (UCSCmm10) using Bowtie2 (v2.2.5). The expression levels for each of the genes were normalized to fragments per kilobase of exon model per million mapped reads (FPKM) using RNA-Seq by Expectation Maximization (RSEM) (v1.2.12), and the common genes among samples were displayed by Venn Charts. NOISeq method was used to screen differentially expressed genes. Cluster and java Treeview were used to perform clustering analysis of the DEGs. The threshold for significant differential expression was based on the Poisson distribution (Fold Change ≥ 2.00 and FDR ≤ 0.001). Using the cor function in R, we calculated the Pearson correlation coefficient (PCC) between each of the two samples. Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by the phyper function in R. With the KEGG annotation result, we classified DEGs according to official classification, and we also performed pathway functional enrichment using phyper, a function of R. We used DIAMOND (Buchfink et al., 2015) to map the DEGs onto the STRING (von Mering et al., 2005) database to obtain the interaction between DEG-encoded proteins using homology with known proteins. For the entire interaction result, we provided an input file that could be imported directly into Cytoscape for network analysis.

Isolation and culture of mouse and human DASCs

Mouse DASC cells were isolated and cultured as previously described (Zuo et al., 2015). Briefly, lung tissue was collected from adult mice and immersed in cold wash buffer (F12 medium, 1% Pen/Strep, 5% FBS). The main bronchi were removed from the lungs and the lobes were cut with sterile surgical blade into small pieces and digested with dissociation buffer (F12/DMEM, 1 mg/ml protease, 0.005% trypsin, and 10 ng/ml DNase I) over night with gentle rocking. Dissociated cells were passed through 70-μm nylon mesh and then washed twice with cold F12 medium.

To isolate human DASCs, bronchoscopy procedure for lung sampling was performed by board-certified respiratory physicians using a flexible fiber-optic bronchoscope (Olympus, Japan). Before bronchoscopy, oropharyngeal and laryngeal anesthesia was obtained by administration of 2 ml of nebulized 4% lidocaine, followed by 1 ml of 2% topical lidocaine sprayed into the patient’s oral and nasal cavities. After the bronchoscope was advanced through the vocal cords, 2 ml of 2% lidocaine solution was instilled into the trachea and both main bronchi through the working channel of the bronchoscope. Then a disposable 2-mm brush was advanced through the working channel of the bronchoscope and used to collect airway epithelial cells by gently gliding the brush back and forth two times in 4–6 order bronchi in the right or left lobe. To isolate the human DASCs, the brush with samples were cut with scissors into 1-cm pieces. After removing sputum, the brush pieces were directly digested with dissociation buffer described above. Specimens were incubated at 37°C for an hour with gentle rocking. Dissociated cells were passed through 70-μm nylon mesh and then washed twice with cold F12 medium. All the human tissues were obtained following clinical SOP under patient’s consent and approved by Shanghai East Hospital Ethics Committee (Shanghai, China). Informed consent was obtained from all subjects and all the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Mouse or human cells were then plated onto feeder cells in DASC culture medium including DMEM/F12, 10% FBS (Hyclone, Australia), Pen/Strep, amphotericin, and growth factor cocktail as previously described. Under 7.5% CO2 culture condition, the DASC colonies emerged 3–5 days after plating, and were digested with 0.25% trypsin-EDTA (Gibco, USA) for 3–5 min for passaging. Typically, DASCs are passaged every 5–7 days and split at 1:7 ratio.

For anchorage-independent growth assay, 1 × 105 cells were seeded in 1 ml of a 0.375% upper agar (Sigma) layer on 0.5% under agar layer in the DMEM supplemented with 10% FBS. Cultures were usually maintained for 14 days, and then gels were stained by crystal violet-methanol solution (Solarbio).

To express LL-37 in stem cells, full-length human CAMP cDNA was cloned from human genome into pHIV-EGFP plasmid vector. Then pHIV-CAMP-EGFP was used to generate lentiviral particles in 293T cells, which was transduced into DASC in combination of 10 μg/ml polybren. pHIV-EGFP lentivirus was transduced for control purpose. The cell viability of cells was assessed by MTT Cell Proliferation and Cytotoxicity Assay Kit.

In vitro antimicrobial assay

Assessment of direct inhibition of bacterial growth by LL-37-DASC or its conditioned medium (CM), which had been incubated with cells for 24 h, was done by counting CFU. Cells or CM in 96-well plates (approx. 1 × 104 cells per well) within culture medium without antibiotics and FBS were pre-incubated with 1 μg/ml anti-LL-37 antibody (HM2070, Hycult biotech) or mouse isotype antibody control (B30010M, Abmart) for 2 h, and then co-cultured with P. aeruginosa or E. coli in a humidified CO2 incubator. Aliquots of culture medium were taken from each well and serially diluted with sterile PBS. Then
they were brought onto a solid medium and evenly spread over the LB-agar surface. After incubation, the number of colonies present on the agar surface was counted, and the number of CFU in the sample was then calculated. For BALF antimicrobial assay, 0.5 ml BALF/per ml, Peprotech, USA), HGF (20 ng/ml, Peprotech, USA), and 5% BSA for 5 days to induce distal lung differentiation. After sphere formation and differentiation, the organoids were harvested, embedded with FGF10 (50 ng/ml, Peprotech, USA), Transferrin (5 µg/ml, Peprotech, USA), HGF (20 ng/ml, Peprotech, USA), and 5% BSA for 5 days to induce distal lung differentiation. After sphere formation and differentiation, the organoids were harvested, embedded in Tissue-Tek O.C.T. Compound (Sakura, USA), and frozen in dry ice and ethanol mixture. For analysis, 5-µm sections were obtained and subjected to immunofluorescence for the indicated mature pulmonary markers, followed by counterstaining with DAPI.

3D organoid culture of DASC

Three-dimensional organoid culture of mouse DASCs was performed on Matrigel matrix (Corning, USA) as previously described. Cells were first cultured in culture medium for 2 days and then transferred to serum-free DMEM/F12 medium supplemented with FGF10 (50 ng/ml, Peprotech, USA), Transferrin (5 µg/ml, Peprotech, USA), HGF (20 ng/ml, Peprotech, USA), and 5% BSA for 5 days to induce distal lung differentiation. After sphere formation and differentiation, the organoids were harvested, embedded in Tissue-Tek O.C.T. Compound (Sakura, USA), and frozen in dry ice and ethanol mixture. For analysis, 5-µm sections were obtained and subjected to immunofluorescence for the indicated mature pulmonary markers, followed by counterstaining with DAPI.

DASC transplantation

Mouse lung was injured by intratracheally instilling with 3 U/kg body weight of bleomycin (Selleckchem, USA) 7 days prior to transplantation. Then mice were anesthetized by isoflurane and rested on a stand. One million GFP-labeled DASCs were suspended in 50 µl of PBS and used for transplantation of each mouse. Intratracheal aspiration was performed by injecting the cells into trachea via mouth. Bright-field and direct fluorescence images of the transplanted lungs were acquired under the fluorescence stereomicroscope (MVX10, Olympus, Japan). Engraftment ratio was then calculated by the area ratio of GFP fluorescence in the lung tissue.

PAO1 and Escherichia coli infection mouse model

Pseudomonas aeruginosa (PAO1, ATCC 9027) and the E. coli strain DH5-α were used to model lung infection in mice as previously described (Torres et al., 2018). Bacterial concentrations were validated by plating on LB-agar and counting colony-forming units (CFU). Before each experiment, the bacterial samples were washed twice and resuspended in PBS. Mice were anesthetized with isoflurane and PAO1 or E. coli (5 × 10⁸ CFUs) were intratracheally instilled into mouse lung. To evaluate whether LL-37-mDASCs show enhanced host defense in vivo, mice were treated with 3 U/kg body weight of bleomycin (Selleckchem, USA) 7 days in advance and then were instilled with bacteria and mDASCs (1 × 10⁹) in a 30 µl total volume. Intratracheal aspiration was performed by instilling the bacteria and cells into the trachea via mouth, which was described in previous publications (Shi et al., 2019). Two days post-infection, mice were sacrificed, and the lung samples and BALFs were collected for analysis. To collect BALF, a 20-gauge catheter was placed into the mouse trachea through which 1 ml of cold PBS was flushed back and forth three times. Aliquots of BALF were diluted and cultured on LB-agar plate for 16 h at 37°C before CFU counting. For lung homogenate harvest, the pulmonary lobes with the stem cell incorporation were separated under the stereomicroscope and then homogenized under sterile conditions. Aliquots of homogenate were diluted and cultured on LB-agar plate for 16 h at 37°C for CFU counting.

Arterial blood gas measurement

Mice were anesthetized and the blood samples were drawn from the carotid aorta into polypropylene syringes containing 60 IU of dry, electrolyte-balanced heparin (PIC070; Radiometer Medical, Copenhagen, Denmark). Partial oxygen pressure (pO₂), partial carbon dioxide pressure (pCO₂), and oxygen saturation (sO₂) were measured by using ABL90 Flex Blood Gas Analyzer (Radiometer Medical).

Decellularization and recellularization of the rat lung

Rat lungs were harvested from male Sprague-Dawley rats and decellularized by perfusion of 0.1% SDS solution and 1% TritonX-100 solution through the trachea at 15 rpm, followed by washing. For recellularization, GFP-labeled WT-hDASCs and LL-37-hDASCs (1 × 10⁶) were delivered to rat lung scaffold, respectively, in 10 ml of media by gravity. Constant media perfusion of serum-free DMEM/F12 medium supplemented with FGF10 (50 ng/ml; Peprotech, USA), Transferrin (5 µg/ml; Peprotech, USA), HGF (20 ng/ml; Peprotech, USA), 2% Matrigel, and 5% BSA through the pulmonary artery was maintained at 4 ml/min and changed daily. Recellularized lungs were maintained in culture for 7 days. For antimicrobial assay, recellularized lung lobes were dissected and co-cultured with PAO1 or E. coli (2 × 10⁶ CFU) in 24-well plates and incubated at 37°C for 24 h, while bacteria were cultured with medium in the control group. Then aliquots of culture medium were diluted and plated on LB-agar plates for bacterial colony number counting.

Real-time qPCR

RNA was isolated from cells or tissue, using the RNeasy mini kit with DNase digestion according to the manufacturer’s instructions (Qiagen). RNA, the quality of which was assessed with SimpliNano (GE Healthcare), was reverse-transcribed into cDNA with PrimeScript™ RT Master Mix (TaKaRa). The Q-PCR was performed on an ABI 7500 real-time PCR system (Applied Biosystems) under following conditions: 95°C for 2 min, then 40 cycles of 95°C for 10 s, and 60°C for 40 s. The relative expression level of genes was calculated using the 2-ΔΔCt method.

Primers: hCAP18/LL-37: F 5'-CACAGCAGTCCACCAAGGATTTG-3', R 5'-GGCC TGTTAGAGGGCTCCT-3'; β-actin: F 5’-CAACAAACAAACTGTAATTCCTCAGT-3’, R 5’-GATCCACCTGCCAGGTTG-3’; IL-6: F 5’-GAGGATTACAACAACAGGC-3’, R 5’-AAGTGACCATCATGGTCTTATACA-3’; TNF-α: F 5’-CATCTTTCCAAATTTGAGTACA-3’, R 5’-TGGGAGTAGAACAAGGTCAC-3’; β-actin: F 5’-TACCCACATGACCAGGACA-3’, R 5’-CTCAAGGAGAGAACTTTGAT-3’; GAPDH: F 5’-CGGAGTCAACGGATTTGTCGT-3’, R 5’-AGGCTCTCTCATGTTGGAAGAC-3’.
Western blotting

Cells or organs were washed with cold PBS and lysed in RIPA buffer (CST) containing protease inhibitors cocktail (Roche) followed by standard Western blotting procedure. To detect the 4-kD LL-37 expression, tissue lysates were centrifuged through Ultra-4 10K Centrifugal Filter Device (Amicon, Millipore) at 4,000 × g for 60 min at 4°C to collect ultrafiltrate whose mass was less than 10-kD. After measuring protein concentration, samples were loaded and separated on 4–20% precast polyacrylamide gels, and then transferred to PVDF membranes (Roche) at 100 V for 10 min. Membranes were blocked with 5% non-fat powdered milk, and then incubated with primary antibodies overnight, followed by secondary antibodies. The specific signals were detected by Immobilon Western Chemiluminescent HRP Substrate (Millipore) and Tanon image system. The following antibodies were used: LL-37/cathelicidin (Santa Cruz, D-5), GAPDH (ab8245, Abcam), and HRP-conjugated anti-mouse IgG (H+L) as secondary antibody (800151, Vazyme).

Statistics

All statistical analyses were performed using GraphPad Prism 7 software. A significance threshold was set at *P < 0.05. All experiments were performed in three independent triplicates at least. P-values are provided in Appendix Table S1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Data availability

The RNA-Seq data are available at the Sequence Read Archive (SRA) https://www.ncbi.nlm.nih.gov/sra (Accession no. PRJNA599606 and PRJNA59986).

Expanded View

For this article is available online.

Acknowledgements

This work was funded by National Key Research Program to WZ (2017YFA0104600), National Science Foundation of China (81770073 to WZ, 81678001 to JFX, 81570007 to JFX, 81600003 to YL). The National Science Fund for Distinguished Young Scholars to JFX (81925001), Shanghai Leading Talent Program (No. 2016036 to JFX), the Key Project of Fundamental Research Funds for the Central Universities (2017ZD002 to JFX), the Project of the Shanghai Hospital Development Center (16CR3086A to JFX), Youth 1000 Talent Plan of China to WZ, Tongji University Basic Scientific Research- interdisciplinary Fund and 985 Grant to WZ, and Shanghai Pulmonary Hospital Annual Grant to WZ.

Author contributions

JFX, WZ, and JMQ designed the study; JFX and WZ supervised the study; YQZ, YS (Yun Shi), LY, YFS (Yufen Sun), and YFH performed experiments; YJYW, YL, YM, and FCJ assisted with the experiments; TZ, TR, and 2XZ contributed new reagents or analytic tools; WZ, JFX, YS, YQZ, and LY drafted the manuscript; JFX, WZ, JMQ, TPD, and NRF provided critical discussion and edited the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Bals R, Weiner Dj, Meegalla RL, Wilson JM (1999a) Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 103: 1113–1117
Bals R, Weiner Dj, Moscioni AD, Meegalla RL, Wilson JM (1999b) Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 67: 6084 – 6089
Bandurska K, Berdowska A, Barczynska-Felusiak R, Krupa P (2015) Unique features of human cathelicidin LL-37. BioFactors 41: 289 – 300
Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, Hogan BL (2013) Type 2 alveolar cells are stem cells in adult lung. J Clin Invest 123: 3025 – 3036
Beaumont PE, McHugh B, Gwyer Findlay E, Mackellar A, Mackenzie KJ, Gallo RL, Govan JR, Simpson AJ, Davidson DJ (2014) Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS One 9: e99029
Buchfink B, Xie C, Huson DH (2015) Fast and sensitive protein alignment using DIAMOND. Nat Methods 12: 59 – 60
Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J et al (2016) Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 196: 2699–2710
Dean SN, Bishop BM, van Hoek ML (2011) Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front Microbiol 2: 128
Easton DM, Nijink A, Mayer ML, Hancock RE (2009) Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 27: 582 – 590
Finlay BB, Hancock RE (2004) Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol 2: 497–504

Fjell CD, Hjaa JA, Hancock RE, Schneider G (2011) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11: 37–51

Gilpin SE, Charest JM, Ren X, Tapia LS, Wu T, Evangelista-Leite D, Mathisen DJ, Ott HC (2016) Regenerative potential of human airway stem cells in lung epithelial engineering. Biomaterials 108: 111–119

Grönborg A, Mahlapuu M, Stahle M, Whately-Smith C, Rollman O (2014) Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 22: 613–621

Hackett NR, Shaykhiev R, Walters MS, Wang R, Zwick RK, Ferris B, Witover B, Salit J, Crystal RG (2011) The human airway epithelial basal cell transcriptome. PLoS One 6: e18378

Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E, Sorensen OE, Weber G, Stahle M (2005) Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 114: 713–719

Imai-Matsushima A, Martin-Sanco I, Karlas A, Imai S, Zorovnic T, Hocke AC, Mollenkopf HJ, Berger H, Meyer TF (2018) Long-term culture of distal airway epithelial cells allows differentiation towards alveolar epithelial cells suited for influenza virus studies. EBioMedicine 33: 230–241

Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B (1998) Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273: 3728–3724

Kovach MA, Ballinger MN, Newsmead MW, Zeng X, Bhan U, Yu FS, Moore BB, Gallo RL, Standiford TJ (2012) Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J Immunol 189: 304–311

Kumar PA, Hu Y, Yamamoto Y, Hoe NB, Wei TS, Mu D, Sun Y, Joo LS, Dagher R, Zielonka EM et al (2011) Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell 147: 525–538

Leeman KT, Fillmore CM, Kim CF (2014) Lung stem and progenitor cells in tissue homeostasis and disease. Curr Top Dev Biol 107: 207–233

Ma Q, Ma Y, Dai X, Ren T, Fu Y, Liu W, Han Y, Wu Y, Cheng Y, Zhang T et al (2018) Regeneration of functional alveoli by adult human SOX9(+ ) airway basal cell transplantation. Protein Cell 9: 267–282

Matute-Bello G, Downey G, Moore BB, Greshong SD, Matthay MA, Slutsky AS, Kuebler WM, Acute Lung Injury in Animals Study Group (2011) An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44: 725–738

von Mering C, Jensen LJ, Niel B, Hooper SD, Krupp M, Flogiennii M, Jouffe N, Huyemen MA, Bork P (2005) STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 33: D433–D437

Nabhan AN, Brownfield DG, Harbury PB, Krasnow MA, Desai TJ (2018) Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359: 1118–1123

Nijink A, Hancock RE (2009) The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 16: 41–47

Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76: 4176–4182

Petersen TH, Caille EA, Zhao L, Lee EJ, Gui L, Raredon MB, Gavrilov K, Yi T, Zhuang ZW, Breuer C et al (2010) Tissue-engineered lungs for in vivo implantation. Science 329: 538–541

Poolew SD, Nawijn MC, Baanng E, Riezebos-Brilman A, van Oosterhout AJ, Kerstens HA, Heijink IH (2015) Increased serum levels of LL-37, HMGB1 and S100A9 during exacerbation in COPD patients. Eur Respir J 45: 1482–1485

Sadelain M, Riviere I, Riddell S (2017) Therapeutic T cell engineering. Nature 545: 423–431

Schaller-Bals S, Schulze A, Bals R (2002) Increased levels of antimicrobial peptides in tracheal aspirates of newborns during infection. Am J Respir Crit Care Med 166: 992–995

Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169: 3883–3891

Shi Y, Dong M, Zhou Y, Li W, Gao Y, Han L, Chen M, Lin H, Zuo W, Jin F (2019) Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice. Stem Cell Res Ther 10: 161

Shu W, Gubitent S, Wang Z, Andi T, Ballard P, Lu MM, Picollo S, Birchmeier W, Whitsett JA, Millar SE et al (2005) Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol 283: 226–239

Soulì M, Galani I, Giannarellou H (2008) Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13: 19045

Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279–1286

Thuretzbacher U, Toney JH (2006) Nature’s clarian call of antibacterial resistance: are we listening? Curr Opin Investig Drugs 7: 158–166

Torres IM, Panatkar YR, Benwin B (2018) Acidosis exaggerates in vivo IL-1-dependent inflammatory responses and neutrophil recruitment during pulmonary Pseudomonas aeruginosa infection. Am J Physiol Lung Cell Mol Physiol 314: L225–L235

Vandamme D, Landuyt B, Luyten W, Schoofs L (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280: 22–35

Vaughan AE, Brumwell AN, Xi Y, Gotts JE, Brownfield DG, Treutlein B, Tan K, Tan V, Liu FC, Looney MR et al (2015) Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature 517: 621–625

Xi Y, Kim T, Brumwell AN, Driver IH, Wei Y, Tan V, Jackson JR, Xu J, Lee DK, Gotts JE et al (2017) Local lung hypoxia determines epithelial fate decisions during alveolar regeneration. Nat Cell Biol 19: 904–914

Yang Y, Riccio P, Schotsaert M, Mori M, Lu J, Lee DK, Garcia-Sastre A, Xu J, Cardoso WV (2018) Spatial-temporal lineage restrictions of embryonic p63(+) progenitors establish distinct stem cell pools in adult airways. Dev Cell 44: 752–761 e754

Yu FS, Cornicelli MD, Kovach MA, Newsmead MW, Zeng X, Kumar A, Gao N, Yoon SC, Gallo RL, Standiford TJ (2010) Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 185: 1142–1149
Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, Zhou S, Cantu E, Morrisey EE (2018) Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555: 251–255
Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389–395
Zuo W, Zhang T, Wu DZ, Guan SP, Liew AA, Yamamoto Y, Wang X, Lim Sj, Vincent M, Lessard M et al (2015) p63(+)Krt5(+) distal airway stem cells are essential for lung regeneration. Nature 517: 616–620

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.